Benzinga | Jun 29, 2021 07:28AM EDT

Raymond James Maintains Outperform on Intellia Therapeutics, Raises Price Target to $168

Raymond James analyst Steven Seedhouse maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and raises the price target from $106 to $168.